Samsara Vision has reported intermediate-term visual and safety outcomes of the SING IMT (Smaller-Incision New-Generation Implantable Miniature Telescope) in patients 6 months post-surgery. According ...
The company plans to initiate a Phase I clinical trial for NRM-823 in the second half of 2025. The Series B round was co-led by Samsara BioCapital and Enavate Sciences, with participation from Pfizer ...
The Series C financing, backed by investors such as The Column Group and Samsara BioCapital, will support the company’s three clinical programmes and further development of its proprietary Imod ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback